
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7174042/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrology Dialysis Transplantation, 2013, 28, 1346-1359.	0.7	628
2	A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines on Acute Kidney Injury: Part 1: definitions, conservative management and contrast-induced nephropathy. Nephrology Dialysis Transplantation, 2012, 27, 4263-4272.	0.7	460
3	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet, The, 2014, 383, 1831-1843.	13.7	341
4	Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearence, and proteinuria in patients with normal renal functions. International Urology and Nephrology, 2007, 39, 1227-1233.	1.4	276
5	A Randomized Study of Allopurinol on Endothelial Function and Estimated Glomular Filtration Rate in Asymptomatic Hyperuricemic Subjects with Normal Renal Function. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1887-1894.	4.5	221
6	Recommendations for the prevention, mitigation and containment of the emerging SARS-CoV-2 (COVID-19) pandemic in haemodialysis centres. Nephrology Dialysis Transplantation, 2020, 35, 737-741.	0.7	215
7	Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrology Dialysis Transplantation, 2016, 31, 337-348.	0.7	206
8	Monocyte count/HDL cholesterol ratio and cardiovascular events in patients with chronic kidney disease. International Urology and Nephrology, 2014, 46, 1619-1625.	1.4	196
9	Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease. Nephrology Dialysis Transplantation, 2009, 24, 1506-1523.	0.7	189
10	Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrology Dialysis Transplantation, 2008, 24, 348-354.	0.7	178
11	Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney International, 2004, 65, 1790-1794.	5.2	149
12	The double challenge of resistant hypertension and chronic kidney disease. Lancet, The, 2015, 386, 1588-1598.	13.7	147
13	Monocyte subpopulations and cardiovascular risk in chronic kidney disease. Nature Reviews Nephrology, 2012, 8, 362-369.	9.6	143
14	Hypertension as an autoimmune and inflammatory disease. Hypertension Research, 2016, 39, 567-573.	2.7	142
15	Vascular calcification: A stiff challenge for the nephrologist. Kidney International, 2004, 66, 1315-1333.	5.2	140
16	Magnesium supplementation helps to improve carotid intima media thickness in patients on hemodialysis. International Urology and Nephrology, 2008, 40, 1075-1082.	1.4	140
17	Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrology Dialysis Transplantation, 2015, 30, 1542-1551.	0.7	140
18	Arterial Stiffness in Renal Patients: An Update. American Journal of Kidney Diseases, 2005, 45, 965-977.	1.9	138

#	Article	IF	CITATIONS
19	Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to Reduce Cardiovascular Events with Aranesp(R) Therapy (TREAT) Study. Nephrology Dialysis Transplantation, 2010, 25, 2846-2850.	0.7	137
20	Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney International, 2013, 84, 998-1008.	5.2	136
21	Epidemiology of renal disease in Romania: a 10 year review of two regional renal biopsy databases. Nephrology Dialysis Transplantation, 2006, 21, 419-424.	0.7	127
22	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 2005-2011.	4.5	124
23	Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. Kidney International, 2014, 86, 1213-1220.	5.2	123
24	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR<45 mL/min/1.73 m2): a summary document from the European Renal Best Practice Group. Nephrology Dialysis Transplantation, 2017, 32, 9-16.	0.7	120
25	Pulmonary Hypertension in CKD. American Journal of Kidney Diseases, 2013, 61, 612-622.	1.9	119
26	Cinacalcet in Patients with Chronic Kidney Disease: A Cumulative Meta-Analysis of Randomized Controlled Trials. PLoS Medicine, 2013, 10, e1001436.	8.4	117
27	Clinical Evidence on Hemodiafiltration: A Systematic Review and a Metaâ€analysis. Seminars in Dialysis, 2014, 27, 119-127.	1.3	117
28	Convective Versus Diffusive Dialysis Therapies for Chronic Kidney Failure: An Updated Systematic Review of Randomized Controlled Trials. American Journal of Kidney Diseases, 2014, 63, 954-967.	1.9	113
29	Heart Failure in Patients with Chronic Kidney Disease: A Systematic Integrative Review. BioMed Research International, 2014, 2014, 1-21.	1.9	107
30	The crosstalk of gut microbiota and chronic kidney disease: role of inflammation, proteinuria, hypertension, and diabetes mellitus. International Urology and Nephrology, 2018, 50, 1453-1466.	1.4	105
31	Posttransplantation Anemia in Adult Renal Allograft Recipients: Prevalence and Predictors. Transplantation, 2006, 81, 1112-1118.	1.0	104
32	Relationship between Serum Magnesium Levels and Cardiovascular Events in Chronic Kidney Disease Patients. American Journal of Nephrology, 2012, 36, 228-237.	3.1	103
33	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. Lancet Diabetes and Endocrinology,the, 2018, 6, 319-331.	11.4	102
34	Increased arterial stiffness in children on haemodialysis. Nephrology Dialysis Transplantation, 2006, 21, 729-735.	0.7	101
35	Serum Sclerostin and Adverse Outcomes in Nondialyzed Chronic Kidney Disease Patients. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1854-E1861.	3.6	99
36	Global variation in renal replacement therapy for end-stage renal disease. Nephrology Dialysis Transplantation, 2011, 26, 2604-2610.	0.7	97

#	Article	IF	CITATIONS
37	Disorders of Lipid Metabolism in Chronic Kidney Disease. Blood Purification, 2018, 46, 144-152.	1.8	95
38	Analysis of the effect of hemodialysis on peripheral and central arterial pressure waveforms. Kidney International, 2000, 57, 2634-2643.	5.2	94
39	Haemodialysis increases QTc interval but not QTc dispersion in ESRD patients without manifest cardiac disease. Nephrology Dialysis Transplantation, 2002, 17, 2170-2177.	0.7	94
40	Predicting mortality in haemodialysis patients: a comparison between lung ultrasonography, bioimpedance data and echocardiography parameters. Nephrology Dialysis Transplantation, 2013, 28, 2851-2859.	0.7	94
41	Anticoagulation in Concomitant Chronic Kidney Disease and AtrialÂFibrillation. Journal of the American College of Cardiology, 2019, 74, 2204-2215.	2.8	94
42	The protein science of biosimilars. Nephrology Dialysis Transplantation, 2006, 21, v4-v8.	0.7	93
43	Erythropoiesis Stimulatory Agent- Resistant Anemia in Dialysis Patients: Review of Causes and Management. Blood Purification, 2010, 29, 1-12.	1.8	93
44	Coronary artery disease in uremia: Etiology, diagnosis, and therapy. Kidney International, 2001, 60, 2059-2078.	5.2	91
45	An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. CKJ: Clinical Kidney Journal, 2020, 13, 981-993.	2.9	89
46	Educating end-stage renal disease patients on dialysis modality selection: clinical advice from the European Renal Best Practice (ERBP) Advisory Board. Nephrology Dialysis Transplantation, 2010, 25, 1757-1759.	0.7	88
47	Vascular calcification in chronic kidney disease. Clinical Science, 2010, 119, 111-121.	4.3	88
48	Serum Uric Acid Level and Endothelial Dysfunction in Patients with Nondiabetic Chronic Kidney Disease. American Journal of Nephrology, 2011, 33, 298-304.	3.1	87
49	Overhydration, Cardiac Function and Survival in Hemodialysis Patients. PLoS ONE, 2015, 10, e0135691.	2.5	87
50	Clinical Practice Guideline on management of older patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m <sup>2</sup> ). Nephrology Dialysis Transplantation, 2016, 31, ii1-ii66.	0.7	87
51	Hypertension in Chronic Kidney Disease Part 2. Hypertension, 2016, 67, 1102-1110.	2.7	86
52	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guidelines: a European Renal Best Practice (ERBP) commentary statement. Nephrology Dialysis Transplantation, 2010, 25, 3823-3831.	0.7	85
53	Evaluation of peritoneal membrane characteristics: clinical advice for prescription management by the ERBP working group. Nephrology Dialysis Transplantation, 2010, 25, 2052-2062.	0.7	85
54	Magnesium in Chronic Kidney Disease: Challenges and Opportunities. Blood Purification, 2010, 29, 280-292.	1.8	83

#	Article	IF	CITATIONS
55	Optimal composition of the dialysate, with emphasis on its influence on blood pressure. Nephrology Dialysis Transplantation, 2004, 19, 785-796.	0.7	82
56	Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrology Dialysis Transplantation, 2014, 29, 232-239.	0.7	81
57	Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: A prospective, crossover study. Nephrology, 2012, 17, 710-717.	1.6	80
58	Illness representations and quality of life scores in haemodialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 2078-2083.	0.7	79
59	COSMOS: the dialysis scenario of CKD–MBD in Europe. Nephrology Dialysis Transplantation, 2013, 28, 1922-1935.	0.7	79
60	Fibroblast Growth Factor 23 and Fetuin A are Independent Predictors for the Coronary Artery Disease Extent in Mild Chronic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1780-1786.	4.5	78
61	Air pollution and kidney disease: review of current evidence. CKJ: Clinical Kidney Journal, 2019, 12, 19-32.	2.9	78
62	Causes and Consequences of Increased Arterial Stiffness in Chronic Kidney Disease Patients. Kidney and Blood Pressure Research, 2007, 30, 97-107.	2.0	77
63	Lipids, blood pressure and kidney update 2014. Pharmacological Research, 2015, 95-96, 111-125.	7.1	77
64	Focus on renal congestion in heart failure. CKJ: Clinical Kidney Journal, 2016, 9, 39-47.	2.9	77
65	Randomized Clinical Trial of the Iron-Based Phosphate Binder PA21 in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 280-289.	4.5	75
66	A retrospective 5-year study in Moldova of acute renal failure due to leptospirosis: 58 cases and a review of the literature. Nephrology Dialysis Transplantation, 2003, 18, 1128-1134.	0.7	74
67	Phosphate – The Silent Stealthy Cardiorenal Culprit in All Stages of Chronic Kidney Disease. Blood Purification, 2009, 27, 220-230.	1.8	73
68	Anemia After Renal Transplantation. American Journal of Kidney Diseases, 2006, 48, 519-536.	1.9	72
69	The impact of acute kidney injury on short-term survival in an Eastern European population with stroke. Nephrology Dialysis Transplantation, 2008, 23, 2228-2234.	0.7	72
70	Gut microbiota and inflammation in chronic kidney disease and their roles in the development of cardiovascular disease. Hypertension Research, 2019, 42, 123-140.	2.7	72
71	Nutritional status evaluation and survival in haemodialysis patients in one centre from Romania. Nephrology Dialysis Transplantation, 2009, 24, 2536-2540.	0.7	70
72	Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. International Urology and Nephrology, 2009, 41, 617-627.	1.4	70

#	Article	IF	CITATIONS
73	Diagnosis of Tuberculosis in Dialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1114-1122.	4.5	70
74	Value of bioimpedance analysis estimated "dry weight―in maintenance dialysis patients: a systematic review and meta-analysis. International Urology and Nephrology, 2017, 49, 2231-2245.	1.4	69
75	Inaccuracy of clinical phenotyping parameters for hypertensive nephrosclerosis. Nephrology Dialysis Transplantation, 2000, 15, 1801-1807.	0.7	66
76	Hypertension and cardiovascular risk assessment in dialysis patients. Nephrology Dialysis Transplantation, 2004, 19, 1058-1068.	0.7	66
77	Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrology Dialysis Transplantation, 2011, 26, 430-437.	0.7	66
78	Silymarin in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Diabetes Research, 2016, 2016, 1-10.	2.3	66
79	Reduced blood pressure diurnal variability as a risk factor for progressive left ventricular dilatation in hemodialysis patients. American Journal of Kidney Diseases, 2000, 35, 617-623.	1.9	65
80	Sleep disorders: a systematic review of an emerging major clinical issue in renal patients. International Urology and Nephrology, 2007, 39, 1217-1226.	1.4	65
81	Causes and Mechanisms of Nondipping Hypertension. Clinical and Experimental Hypertension, 2008, 30, 585-597.	1.3	65
82	Hyperphosphatemia in patients with ESRD: assessing the current evidence linking outcomes with treatment adherence. BMC Nephrology, 2013, 14, 153.	1.8	64
83	The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study. Nephrology Dialysis Transplantation, 2010, 25, 2722-2730.	0.7	63
84	Criteria for and Appropriateness of Renal Transplantation in Elderly Patients With End-Stage Renal Disease. Transplantation, 2016, 100, e55-e65.	1.0	63
85	Hypertension in Chronic Kidney Disease Part 1. Hypertension, 2016, 67, 1093-1101.	2.7	63
86	Biosimilars and biopharmaceuticals: what the nephrologists need to knowa position paper by the ERA-EDTA Council. Nephrology Dialysis Transplantation, 2008, 23, 3731-3737.	0.7	62
87	Renal Anemia of Inflammation: The Name Is Self-Explanatory. Blood Purification, 2011, 32, 220-225.	1.8	62
88	Does pre-emptive transplantation versus post start of dialysis transplantation with a kidney from a living donor improve outcomes after transplantation? A systematic literature review and position statement by the Descartes Working Group and ERBP. Nephrology Dialysis Transplantation, 2016, 31, 691-697.	0.7	62
89	The impact of exercise on physical function, cardiovascular outcomes and quality of life in chronic kidney disease patients: a systematic review. International Urology and Nephrology, 2018, 50, 885-904.	1.4	62
90	A multicentric, international matched pair analysis of body composition in peritoneal dialysis versus haemodialysis patients. Nephrology Dialysis Transplantation, 2013, 28, 2620-2628.	0.7	61

#	Article	IF	CITATIONS
91	Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. The Cochrane Library, 2015, 2015, CD006258.	2.8	61
92	Arterial wave reflections and mortality in haemodialysis patients—only relevant in elderly, cardiovascularly compromised?. Nephrology Dialysis Transplantation, 2006, 21, 2859-2866.	0.7	60
93	Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: effects on blood pressure, hydration status, and arterial stiffness. International Urology and Nephrology, 2012, 44, 583-591.	1.4	60
94	Lipid, blood pressure and kidney update 2013. International Urology and Nephrology, 2014, 46, 947-961.	1.4	60
95	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. Nephrology Dialysis Transplantation, 2016, 31, 1982-1988.	0.7	60
96	Effects of Volume Overload and Current Techniques for the Assessment of Fluid Status in Patients with Renal Disease. Blood Purification, 2018, 46, 34-47.	1.8	60
97	European best practice quo vadis? From European best practice guidelines (EBPG) to European renal best practice (ERBP). Nephrology Dialysis Transplantation, 2008, 23, 2162-2166.	0.7	59
98	An Update on Coronary Artery Disease and Chronic Kidney Disease. International Journal of Nephrology, 2014, 2014, 1-9.	1.3	59
99	Factors affecting the quality of life of haemodialysis patients from Romania: a multicentric study. Nephrology Dialysis Transplantation, 2008, 24, 626-629.	0.7	58
100	A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrology Dialysis Transplantation, 2013, 28, 2383-2392.	0.7	58
101	Uric Acid in Hypertension and Renal Disease: The Chicken or the Egg. Blood Purification, 2010, 30, 288-295.	1.8	57
102	The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney International Supplements, 2011, 1, 6-9.	14.2	57
103	Obstructive sleep apnea syndrome is related to the progression of chronic kidney disease. International Urology and Nephrology, 2012, 44, 535-539.	1.4	57
104	The relationship between chronic volume overload and elevated blood pressure in hemodialysis patients: use of bioimpedance provides a different perspective from echocardiography and biomarker methodologies. International Urology and Nephrology, 2010, 42, 789-797.	1.4	56
105	Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes, Obesity and Metabolism, 2019, 21, 2368-2383.	4.4	56
106	Successful use of Molecular Absorbent Regenerating System (MARS) dialysis for the treatment of fulminant hepatic failure in children accidentally poisoned by toxic mushroom ingestion. Liver International, 2003, 23, 21-27.	3.9	55
107	Serum Vitamin D Levels are Independently Associated with Severity of Coronary Artery Disease. Journal of Investigative Medicine, 2012, 60, 869-873.	1.6	54
108	The Relationship between IL-10 Levels and Cardiovascular Events in Patients with CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1207-1216.	4.5	54

#	Article	IF	CITATIONS
109	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
110	The Role of Plasma Triglyceride/Highâ€Density Lipoprotein Cholesterol Ratio to Predict New Cardiovascular Events in Essential Hypertensive Patients. Journal of Clinical Hypertension, 2016, 18, 772-777.	2.0	53
111	Capillary rarefaction from the kidney point of view. CKJ: Clinical Kidney Journal, 2018, 11, 295-301.	2.9	52
112	Arterial stiffness in dialysis patients: where are we now?. International Urology and Nephrology, 2010, 42, 741-752.	1.4	51
113	Role of Klotho in the Development of Essential Hypertension. Hypertension, 2021, 77, 740-750.	2.7	51
114	Insights from ambulatory blood pressure monitoring: diagnosis of hypertension and diurnal blood pressure in renal transplant recipients. Transplantation, 2004, 77, 849-853.	1.0	50
115	Vascular calcification in chronic kidney disease: are biomarkers useful for probing the pathobiology and the health risks of this process in the clinical scenario?. Nephrology Dialysis Transplantation, 2014, 29, 1275-1284.	0.7	50
116	Influence of Body Mass Index on the Association of Weight Changes with Mortality in Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1725-1733.	4.5	49
117	Lipids, blood pressure and kidney update 2015. Lipids in Health and Disease, 2015, 14, 167.	3.0	49
118	Sudden Death in Hemodialysis: An Update. Blood Purification, 2010, 30, 135-145.	1.8	48
119	Persistence of Cardiovascular Risk Factors in Women with Previous Preeclampsia: A Long-term Follow-up Study. Journal of Investigative Medicine, 2015, 63, 641-645.	1.6	48
120	Pulse Wave Velocity Ratio. Hypertension, 2015, 65, 289-290.	2.7	48
121	Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Archives of Medical Science, 2017, 4, 897-913.	0.9	48
122	Use of Lung Ultrasound for the Assessment of Volume Status in CKD. American Journal of Kidney Diseases, 2018, 71, 412-422.	1.9	48
123	Relationship between Uric Acid and Subtle Cognitive Dysfunction in Chronic Kidney Disease. American Journal of Nephrology, 2011, 34, 49-54.	3.1	47
124	Dry weight assessment by combined ultrasound and bioimpedance monitoring in low cardiovascular risk hemodialysis patients: a randomized controlled trial. International Urology and Nephrology, 2017, 49, 143-153.	1.4	47
125	Mean corpuscular volume is associated with endothelial dysfunction and predicts composite cardiovascular events in patients with chronic kidney disease. Nephrology, 2013, 18, 728-735.	1.6	46
126	Sclerostin, cardiovascular disease and mortality: a systematic review and meta-analysis. International Urology and Nephrology, 2016, 48, 2029-2042.	1.4	46

#	Article	IF	CITATIONS
127	Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) – A systematic review and meta-analysis. PLoS ONE, 2017, 12, e0187025.	2.5	46
128	Allopurinol, uric acid, and oxidative stress in cardiorenal disease. International Urology and Nephrology, 2011, 43, 441-449.	1.4	45
129	A randomized multicenter trial on a lung ultrasound–guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. Kidney International, 2021, 100, 1325-1333.	5.2	45
130	Uric Acid and Pentraxin-3 Levels Are Independently Associated with Coronary Artery Disease Risk in Patients with Stage 2 and 3 Kidney Disease. American Journal of Nephrology, 2011, 33, 325-331.	3.1	44
131	Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow—implications for CKD and cardiovascular disease. Kidney International Supplements, 2011, 1, 10-12.	14.2	44
132	Clinical usefulness of novel prognostic biomarkers in patients on hemodialysis. Nature Reviews Nephrology, 2012, 8, 141-150.	9.6	44
133	Sirolimus - Challenging Current Perspectives. Therapeutic Drug Monitoring, 2006, 28, 577-584.	2.0	42
134	Effects of Allopurinol on Endothelial Dysfunction: A Meta-Analysis. American Journal of Nephrology, 2014, 39, 348-356.	3.1	42
135	Bioimpedance analysis versus lung ultrasonography for optimal risk prediction in hemodialysis patients. International Journal of Cardiovascular Imaging, 2016, 32, 263-270.	1.5	42
136	Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. Journal of Nephrology, 2006, 19, 794-801.	2.0	42
137	Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrology Dialysis Transplantation, 2008, 24, 719-727.	0.7	41
138	The Influence of Dialytic Modality on Arterial Stiffness, Pulse Wave Reflections, and Vasomotor Function. Peritoneal Dialysis International, 2004, 24, 365-372.	2.3	40
139	Real-World Impact of Cardiovascular Disease and Anemia on Quality of Life and Productivity in Patients with Non-Dialysis-Dependent Chronic Kidney Disease. Advances in Therapy, 2017, 34, 1662-1672.	2.9	40
140	Effect of renin–angiotensin–aldosterone system blockade in adults with diabetes mellitus and advanced chronic kidney disease not on dialysis: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2018, 33, 12-22.	0.7	39
141	The Effects of Bariatric Surgery on Renal Outcomes: a Systematic Review and Meta-analysis. Obesity Surgery, 2018, 28, 3815-3833.	2.1	39
142	Methods and potential biomarkers for the evaluation of endothelial dysfunction in chronic kidney disease: A critical approach. Journal of the American Society of Hypertension, 2010, 4, 116-127.	2.3	38
143	Serum Uric Acid and Risk for Acute Kidney Injury Following Contrast. Angiology, 2017, 68, 132-144.	1.8	38
144	Prevalence and Management of Anaemia in Renal Transplant Recipients: Data from Ten European Centres. Nephron Clinical Practice, 2011, 117, c127-c134.	2.3	37

#	Article	IF	CITATIONS
145	Cardiovascular and non-cardiovascular mortality in dialysis patients: where is the link?. Kidney International Supplements, 2011, 1, 21-23.	14.2	37
146	Dialysis modality choice in elderly patients with end-stage renal disease: a narrative review of the available evidence: TableÂ1 Nephrology Dialysis Transplantation, 2017, 32, gfv411.	0.7	37
147	The Effects of Vitamin D Therapy on Left Ventricular Structure and Function – Are These the Underlying Explanations for Improved CKD Patient Survival?. Nephron Clinical Practice, 2010, 116, c187-c195.	2.3	36
148	The prevalence of chronic kidney disease in the general population in Romania: a study on 60,000 persons. International Urology and Nephrology, 2012, 44, 213-220.	1.4	36
149	Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrology Dialysis Transplantation, 2013, 28, 1241-1254.	0.7	36
150	A systematic review regarding the association of illness perception and survival among end-stage renal disease patients. Nephrology Dialysis Transplantation, 2013, 28, 2407-2414.	0.7	36
151	Global differences in dialysis modality mix: the role of patient characteristics, macroeconomics and renal service indicators. Nephrology Dialysis Transplantation, 2013, 28, 1264-1275.	0.7	35
152	Protein-energy wasting, as well as overweight and obesity, is a long-term risk factor for mortality in chronic hemodialysis patients. International Urology and Nephrology, 2014, 46, 615-621.	1.4	35
153	Systematic Review of the Evidence Underlying the Association Between Mineral Metabolism Disturbances and Risk of Fracture and Need for Parathyroidectomy in CKD. American Journal of Kidney Diseases, 2009, 53, 1002-1013.	1.9	34
154	Relationship Between Elevated Morning Blood Pressure Surge, Uric Acid, and Cardiovascular Outcomes in Hypertensive Patients. Journal of Clinical Hypertension, 2014, 16, 530-535.	2.0	34
155	Phosphodiesterase type 5 inhibitors and kidney disease. International Urology and Nephrology, 2015, 47, 1521-1528.	1.4	34
156	Novel Faces of Fibroblast Growth Factor 23 (FGF23): Iron Deficiency, Inflammation, Insulin Resistance, Left Ventricular Hypertrophy, Proteinuria and Acute Kidney Injury. Calcified Tissue International, 2017, 100, 217-228.	3.1	34
157	Salt Intake and Immunity. Hypertension, 2018, 72, 19-23.	2.7	34
158	Endocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease?. Journal of Clinical Hypertension, 2014, 16, 914-916.	2.0	33
159	New insights into the effect of haemodiafiltration on mortality: the Romanian experience. Nephrology Dialysis Transplantation, 2015, 30, 294-301.	0.7	32
160	Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide. Nephrology Dialysis Transplantation, 2017, 32, gfw242.	0.7	32
161	Should a fistula first policy be revisited in elderly haemodialysis patients?. Nephrology Dialysis Transplantation, 2019, 34, 1636-1643.	0.7	32
162	The effect of chronic kidney disease on lipid metabolism. International Urology and Nephrology, 2019, 51, 265-277.	1.4	32

#	Article	IF	CITATIONS
163	Ambulatory blood pressure monitoring in renal transplantation: should ABPM be routinely performed in renal transplant patients?. Transplantation, 2003, 76, 1640-1642.	1.0	31
164	Elevated Serum Uric Acid Predicts Angiographic Impaired Reperfusion and 1-Year Mortality in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention. Journal of Investigative Medicine, 2011, 59, 931-937.	1.6	31
165	Obstructive sleep apnea syndrome and chronic kidney disease: a new cardiorenal risk factor. Clinical and Experimental Hypertension, 2014, 36, 211-216.	1.3	31
166	Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis. International Urology and Nephrology, 2015, 47, 563-569.	1.4	31
167	The challenge of cardiovascular risk factors in end-stage renal disease. Journal of Nephrology, 2003, 16, 476-86.	2.0	31
168	Dynamics of the Circadian Blood Pressure Profiles after Renal Transplantation. Transplantation, 2005, 80, 1168-1173.	1.0	30
169	Direct renin inhibitors: the dawn of a new era, or just a variation on a theme?. Nephrology Dialysis Transplantation, 2007, 22, 2435-2439.	0.7	30
170	Religiosity, spirituality and quality of life of dialysis patients: a systematic review. International Urology and Nephrology, 2019, 51, 839-850.	1.4	30
171	"Celebrating old age†an obsolete expression during the COVID-19 pandemic? Medical, social, psychological, and religious consequences of home isolation and loneliness among the elderly. Archives of Medical Science, 2021, 17, 285-295.	0.9	30
172	The Role of the Renin-Angiotensin-Aldosterone System in Renal Artery Stenosis, Renovascular Hypertension, and Ischemic Nephropathy: Diagnostic Implications. Progress in Cardiovascular Diseases, 2009, 52, 204-208.	3.1	29
173	Exploring the Association between Macroeconomic Indicators and Dialysis Mortality. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1655-1663.	4.5	29
174	The role of sodium intake in nephrolithiasis: epidemiology, pathogenesis, and future directions. European Journal of Internal Medicine, 2016, 35, 16-19.	2.2	29
175	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. CKJ: Clinical Kidney Journal, 2019, 12, 269-280.	2.9	29
176	Associations between Serum Leptin Level and Bone Turnover in Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 2297-2304.	4.5	28
177	Uraemic toxins versus volume and water as the major factor that matters with dialysis. Nephrology Dialysis Transplantation, 2012, 27, 58-62.	0.7	28
178	Novel techniques and innovation in blood purification: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney International, 2013, 83, 359-371.	5.2	28
179	Is it time for spironolactone therapy in dialysis patients?. Nephrology Dialysis Transplantation, 2006, 21, 854-858.	0.7	27
180	Erythropoiesis-Stimulating Agents (ESA) for Preventing the Progression of Chronic Kidney Disease: A Meta-Analysis of 19 Studies. American Journal of Nephrology, 2014, 40, 263-279.	3.1	27

#	Article	IF	CITATIONS
181	Morning Blood Pressure Surge as a Predictor of Development of Chronic Kidney Disease. Journal of Clinical Hypertension, 2016, 18, 444-448.	2.0	27
182	Acute effects of salt on blood pressure are mediated by serum osmolality. Journal of Clinical Hypertension, 2018, 20, 1447-1454.	2.0	27
183	Antidiuretic Hormone and Serum Osmolarity Physiology and Related Outcomes: What Is Old, What Is New, and What Is Unknown?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5406-5420.	3.6	27
184	Using Artificial Intelligence Resources in Dialysis and Kidney Transplant Patients: A Literature Review. BioMed Research International, 2020, 2020, 1-14.	1.9	27
185	Cardiovascular disease in renal allograft recipients is associated with elevated sialic acid or markers of inflammation. Clinical Transplantation, 2004, 18, 201-204.	1.6	26
186	Haemodialysis acutely improves endothelium-independent vasomotor function without significantly influencing the endothelium-mediated abnormal response to a Â2-agonist. Nephrology Dialysis Transplantation, 2004, 19, 637-643.	0.7	26
187	Elevated plasma asymmetric dimethylarginine level in acute myocardial infarction patients as a predictor of poor prognosis and angiographic impaired reperfusion. Atherosclerosis, 2011, 219, 304-310.	0.8	26
188	A longitudinal study on illness perceptions in hemodialysis patients: changes over time. Archives of Medical Science, 2013, 5, 831-836.	0.9	26
189	Hyperuricemia is associated with progression of IgA nephropathy. International Urology and Nephrology, 2015, 47, 673-678.	1.4	26
190	Association of Serum Uric Acid Level With Blood Pressure Variability in Newly Diagnosed Essential Hypertension. Journal of Clinical Hypertension, 2015, 17, 929-935.	2.0	26
191	Is Kt/V useful in elderly dialysis patients? Pro and Con arguments. Nephrology Dialysis Transplantation, 2018, 33, 742-750.	0.7	26
192	Systemic Vasculitis: Still a Challenging Disease. American Journal of Kidney Diseases, 2005, 46, 173-185.	1.9	25
193	Post-transplantation anaemia in adult and paediatric renal allograft recipients—Guy's Hospital experience. Nephrology Dialysis Transplantation, 2006, 21, 1974-1980.	0.7	25
194	Procalcitonin: diagnostic value in systemic infections in chronic kidney disease or renal transplant patients. International Urology and Nephrology, 2014, 46, 461-468.	1.4	25
195	Endostatin in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events and survival. European Journal of Internal Medicine, 2016, 33, 81-87.	2.2	25
196	Brain-kidney cross-talk: Definition and emerging evidence. European Journal of Internal Medicine, 2016, 36, 7-12.	2.2	25
197	Dietary and commercialized fructose: Sweet or sour?. International Urology and Nephrology, 2017, 49, 1611-1620.	1.4	25
198	The predictive value of malnutrition for functional and cognitive status in elderly hemodialysis patients. International Urology and Nephrology, 2019, 51, 155-162.	1.4	25

#	Article	IF	CITATIONS
199	Nebivolol Improves Renal Function in Patients Who Underwent Angioplasty due to Renal Artery Stenosis: A Pilot Study. Nephron Clinical Practice, 2010, 114, c213-c217.	2.3	24
200	Educating end-stage renal disease patients on dialysis modality selection. CKJ: Clinical Kidney Journal, 2010, 3, 225-233.	2.9	24
201	The complexity of the cardio–renal link: taxonomy, syndromes, and diseases. Kidney International Supplements, 2011, 1, 2-5.	14.2	24
202	Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrology, 2013, 14, 144.	1.8	24
203	Predictive Value for Galectin 3 and Cardiotrophin 1 in Hemodialysis Patients. Angiology, 2016, 67, 854-859.	1.8	24
204	Thyroid function and cardiovascular events in chronic kidney disease patients. Journal of Nephrology, 2017, 30, 235-242.	2.0	24
205	Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker. Acta Diabetologica, 2021, 58, 81-91.	2.5	24
206	Relation between Serum Calcium, Phosphate, Parathyroid Hormone and â€~Nondipper' Circadian Blood Pressure Variability Profile in Patients with Normal Renal Function. American Journal of Nephrology, 2007, 27, 516-521.	3.1	23
207	Evaluation of advanced glycation end products accumulation, using skin autofluorescence, in CKD and dialysis patients. International Urology and Nephrology, 2012, 44, 1441-1449.	1.4	23
208	Uric Acid Level and Erectile Dysfunction in Patients with Coronary Artery Disease. Journal of Sexual Medicine, 2014, 11, 165-172.	0.6	23
209	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrology Dialysis Transplantation, 2015, 30, 698-700.	0.7	23
210	Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrology Dialysis Transplantation, 2019, 34, 673-681.	0.7	23
211	Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrology Dialysis Transplantation, 2019, 34, 923-933.	0.7	23
212	Relation between Serum Thyroid Hormone and â€~Nondipper' Circadian Blood Pressure Variability. Kidney and Blood Pressure Research, 2007, 30, 416-420.	2.0	22
213	Mineral and bone disorder after renal transplantation: a review. International Urology and Nephrology, 2008, 40, 171-184.	1.4	22
214	Osteoprotegerin in Chronic Kidney Disease: Associations with Vascular Damage and Cardiovascular Events. Calcified Tissue International, 2016, 99, 121-130.	3.1	22
215	Effect of Uric Acid-Lowering Agents on Cardiovascular Outcome in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. Angiology, 2020, 71, 315-323.	1.8	22
216	Health-related quality of life in patients with chronic kidney disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 43-54.	1.4	22

#	Article	IF	CITATIONS
217	Uric Acid as a Cardiometabolic Risk Factor: To Be or Not to Be. Contributions To Nephrology, 2011, 171, 62-67.	1.1	21
218	Vascular Access Type, Health-Related Quality of Life, and Depression in Hemodialysis Patients: A Preliminary Report. Journal of Vascular Access, 2012, 13, 215-220.	0.9	21
219	Ambulatory blood pressure monitoring: from old concepts to novel insights. International Urology and Nephrology, 2012, 44, 173-182.	1.4	21
220	Adverse Impact of Desulfovibrio spp. and Beneficial Role of Anaerostipes spp. on Renal Function: Insights from a Mendelian Randomization Analysis. Nutrients, 2020, 12, 2216.	4.1	21
221	Current management of secondary hyperparathyroidism: a multicenter observational study (COSMOS). Journal of Nephrology, 2008, 21, 290-8.	2.0	21
222	Nephrology and renal replacement therapy in Romaniatransition still continues (Cinderella story) Tj ETQq0 0 0	rgBT /Ovei 0.7	rlock 10 Tf 50

223	Negative outcome studies in end-stage renal disease: how dark are the storm clouds?. Nephrology Dialysis Transplantation, 2007, 23, 56-61.	0.7	20
224	Outcomes of dialytic modalities in a large incident registry cohort from Eastern Europe: the Romanian Renal Registry. International Urology and Nephrology, 2014, 46, 443-451.	1.4	20
225	Relevance of uric acid and asymmetric dimethylarginine for modeling cardiovascular risk prediction in chronic kidney disease patients. International Urology and Nephrology, 2016, 48, 1129-1136.	1.4	20
226	An analysis of the impact of fluid overload and fluid depletion for all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation, 2019, 34, 1385-1393.	0.7	20
227	Effect of sodium–glucose cotransporter 2 inhibitors on hemoglobin and hematocrit levels in type 2 diabetes: a systematic review and meta-analysis. International Urology and Nephrology, 2022, 54, 827-841.	1.4	20
228	Serial echocardiographic changes in patients on hemodialysis: an evaluation of guideline implementation. Journal of Nephrology, 2006, 19, 783-93.	2.0	20
229	Ambulatory blood pressure monitoring: an essential tool for blood pressure assessment in uraemic patients. Nephrology Dialysis Transplantation, 2002, 17, 1737-1741.	0.7	19
230	Treatment of Proliferative Lupus Nephritis—A Critical Approach. Seminars in Arthritis and Rheumatism, 2007, 36, 224-237.	3.4	19
231	Stimulating Erythropoiesis: Future Perspectives. Kidney and Blood Pressure Research, 2008, 31, 234-246.	2.0	19
232	Superior Predictive Value for NTproBNP Compared with High Sensitivity cTnT in Dialysis Patients: A Pilot Prospective Observational Study. Kidney and Blood Pressure Research, 2014, 39, 636-647.	2.0	19
233	Electrocardiogram abnormalities and heart rate variability in predicting mortality and cardiovascular events among hemodialyzed patients. International Urology and Nephrology, 2015, 47, 1703-1708.	1.4	19
234	Colchicine in Renal Medicine: New Virtues of an Ancient Friend. Blood Purification, 2017, 43, 125-135.	1.8	19

#	Article	IF	CITATIONS
235	B-lines score on lung ultrasound as a direct measure of respiratory dysfunction in ICU patients with acute kidney injury. International Urology and Nephrology, 2018, 50, 113-119.	1.4	19
236	Statin treatment for dyslipidemia in chronic kidney disease and renal transplantation: a review of the evidence. Journal of Nephrology, 2009, 22, 598-609.	2.0	19
237	Intradialytic changes in reflective properties of the arterial system during a single hemodialysis session. Hemodialysis International, 2005, 9, 376-382.	0.9	18
238	The Success Story of Peritoneal Dialysis in Romania: Analysis of Differences in Mortality by Dialysis Modality and Influence of Risk Factors in a National Cohort. Peritoneal Dialysis International, 2006, 26, 266-275.	2.3	18
239	Kidney and braina renal perspective of 'Les Liaisons Dangereuses'. Nephrology Dialysis Transplantation, 2010, 25, 1370-1373.	0.7	18
240	Changes in arterial stiffness following dialysis in relation to overhydration and to endothelial function. International Urology and Nephrology, 2012, 44, 897-905.	1.4	18
241	Serum gamma-glutamyltransferase levels are inversely related to endothelial function in chronic kidney disease. International Urology and Nephrology, 2013, 45, 1071-1078.	1.4	18
242	Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice. Nephrology Dialysis Transplantation, 2015, 32, gfv365.	0.7	18
243	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
244	The Future of IL-1 Targeting in Kidney Disease. Drugs, 2018, 78, 1073-1083.	10.9	18
245	Multilayered Interplay Between Fructose and Salt in Development of Hypertension. Hypertension, 2019, 73, 265-272.	2.7	18
246	Atherosclerotic Renal Artery Stenosis Prevalence and Correlations in Acute Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Interventions: Data From Nonrandomized Singleâ€Center Study (RENâ€ACS)—A Single Center, Prospective, Observational Study. Journal of the American Heart Association, 2015, 4, e002379.	3.7	17
247	Effect of Coffee Consumption on Renal Outcome: A Systematic Review and Meta-Analysis of Clinical Studies. , 2021, 31, 5-20.		17
248	How important and how treatable is vascular stiffness as a cardiovascular risk factor in renal failure?. Nephrology Dialysis Transplantation, 2002, 17, 965-969.	0.7	16
249	Time to Reconsider Evidence for Anaemia Treatment (TREAT) = Essential Safety Arguments (ESA). Nephrology Dialysis Transplantation, 2010, 25, 1734-1737.	0.7	16
250	Novel Masters of Erythropoiesis: Hypoxia Inducible Factors and Recent Advances in Anemia of Renal Disease. Blood Purification, 2016, 42, 160-167.	1.8	16
251	Bleeding in advanced CKD patients on antithrombotic medication – A critical appraisal. Pharmacological Research, 2018, 129, 535-543.	7.1	16
252	Systolic Blood Pressure Diurnal Variation is Not a Predictor of Renal Target Organ Damage in Kidney Transplant Recipients. American Journal of Transplantation, 2004, 4, 244-247.	4.7	15

#	Article	IF	CITATIONS
253	Through the looking glass: the protein science of biosimilars. Clinical and Experimental Nephrology, 2007, 11, 191-195.	1.6	15
254	The use of echocardiography in observational clinical trials: the EURECA-m registry. Nephrology Dialysis Transplantation, 2013, 28, 19-23.	0.7	15
255	Time to Improve Fluid Management in Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1474-1475.	4.5	15
256	Increased arterial stiffness predicts cognitive impairment in hemodialysis patients. Hemodialysis International, 2016, 20, 463-472.	0.9	15
257	Clinical value of ambulatory blood pressure: Is it time to recommend for all patients with hypertension?. Clinical and Experimental Nephrology, 2016, 20, 14-22.	1.6	15
258	Predictive abilities of baseline measurements of fluid overload, assessed by bioimpedance spectroscopy and serum N-terminal pro-B-type natriuretic peptide, for mortality in hemodialysis patients. Archives of Medical Science, 2017, 5, 1121-1129.	0.9	15
259	Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Medicine, 2018, 16, 158.	5.5	15
260	Nephrology in the Eastern and Central European region: challenges and opportunities. Kidney International, 2019, 96, 287-290.	5.2	15
261	Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis. Nephrology Dialysis Transplantation, 2006, 22, 59-63.	0.7	14
262	Atrial fibrillation in chronic kidney disease. European Journal of Internal Medicine, 2016, 33, 3-13.	2.2	14
263	The quest for equilibrium: exploring the thin red line between bleeding and ischaemic risks in the management of acute coronary syndromes in chronic kidney disease patients. Nephrology Dialysis Transplantation, 2017, 32, 1967-1976.	0.7	14
264	Magnesium supplementation: A consideration in dialysis patients. Seminars in Dialysis, 2018, 31, 11-14.	1.3	14
265	A journey from microenvironment to macroenvironment: the role of metaflammation and epigenetic changes in cardiorenal disease. CKJ: Clinical Kidney Journal, 2019, 12, 861-870.	2.9	14
266	Cardioprotective apelin effects and the cardiac-renal axis: review of existing science and potential therapeutic applications of synthetic and native regulated apelin. Journal of Human Hypertension, 2019, 33, 429-435.	2.2	14
267	Extracorporeal Membrane Oxygenation in Cardiogenic Shock due to Acute Myocardial Infarction: A Systematic Review. BioMed Research International, 2020, 2020, 1-9.	1.9	14
268	The epidemics of cardiovascular disease in elderly patients with chronic kidney disease – Two facets of the same problem. International Urology and Nephrology, 2006, 38, 371-379.	1.4	13
269	Trace elements in end-stage renal disease – unfamiliar territory to be revealed. BMC Nephrology, 2009, 10, 12.	1.8	13
270	Changes in the histological spectrum of glomerular diseases in the past 16 years in the North-Eastern region of Romania. BMC Nephrology, 2013, 14, 148.	1.8	13

#	Article	IF	CITATIONS
271	Hepatitis B and C Virus Infection in the Hemodialysis Population from Three Romanian Regions. Nephron, 2015, 129, 202-208.	1.8	13
272	Protein convertase subtilisin/kexin type 9 biology in nephrotic syndrome: implications for use as therapy. Nephrology Dialysis Transplantation, 2020, 35, 1663-1674.	0.7	13
273	The Effect of Urine pH and Urinary Uric Acid Levels on the Development of Contrast Nephropathy. Kidney and Blood Pressure Research, 2020, 45, 131-141.	2.0	13
274	Mitochondrion-driven nephroprotective mechanisms of novel glucose lowering medications. Mitochondrion, 2021, 58, 72-82.	3.4	13
275	Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease. Journal of Nephrology, 2021, 34, 649-659.	2.0	13
276	What would we like to know, and what do we not know about fibroblast growth factor 23. Journal of Nephrology, 2011, 24, 696-706.	2.0	13
277	Influencing Cardiovascular Outcomes through Heart Rate Variability Modulation: A Systematic Review. Diagnostics, 2021, 11, 2198.	2.6	13
278	Relationships between blood pressure variability and left ventricular parameters in haemodialysis and renal transplant patients. Nephrology, 1998, 4, 87-93.	1.6	12
279	Acute effect of CyA A (Neoral®) on large artery hemodynamics in renal transplant patients. Kidney International, 2005, 67, 732-737.	5.2	12
280	Sudden Cardiac Death in Patients with Chronic Kidney Disease: Prevention Is the sine qua non. Kidney and Blood Pressure Research, 2011, 34, 269-276.	2.0	12
281	Priority topics for European multidisciplinary guidelines on the management of chronic kidney disease in older adults. International Urology and Nephrology, 2016, 48, 859-869.	1.4	12
282	Coexistent papillary thyroid carcinoma diagnosed in surgically treated patients for primary versus secondary hyperparathyroidism: same incidence, different characteristics. BMC Surgery, 2019, 19, 94.	1.3	12
283	Rapid decline of kidney function in diabetic kidney disease is associated with high soluble Klotho levels. Nefrologia, 2019, 39, 250-257.	0.4	12
284	The Speed of Ingestion of a Sugary Beverage Has an Effect on the Acute Metabolic Response to Fructose. Nutrients, 2021, 13, 1916.	4.1	12
285	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Vascular Calcification—A New Window on the Cardiovascular System: Role of Agents Used to Manipulate Skeletal Integrity. Seminars in Dialysis, 2007, 20, 158-169.	1.3	11
286	Renal Anemia: Comparing Current Eastern and Western European Management Practice (ORAMA). Renal Failure, 2008, 30, 267-276.	2.1	11
287	Major pathways of the reno–cardiovascular link: the sympathetic and renin–angiotensin systems. Kidney International Supplements, 2011, 1, 13-16.	14.2	11
288	Electrocardiographic P-wave characteristics in patients with end-stage renal disease: P-index and interatrial block. International Urology and Nephrology, 2013, 45, 511-517.	1.4	11

#	Article	IF	CITATIONS
289	Low serum pancreatic enzyme levels predict mortality and are associated with malnutrition–inflammation–atherosclerosis syndrome in patients with chronic kidney disease. International Urology and Nephrology, 2013, 45, 477-484.	1.4	11
290	State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists. International Urology and Nephrology, 2015, 47, 1529-1539.	1.4	11
291	PTH and/or Bone Histology: Are We Still Waiting for a Verdict From the CKD-MBD Grand Jury?. American Journal of Kidney Diseases, 2016, 67, 535-538.	1.9	11
292	Clinical imaging of vascular disease in chronic kidney disease. International Urology and Nephrology, 2016, 48, 827-837.	1.4	11
293	Positioning novel biologicals in CKD-mineral and bone disorders. Journal of Nephrology, 2017, 30, 689-699.	2.0	11
294	Addition of silymarin to renin–angiotensin system blockers in normotensive patients with type 2 diabetes mellitus and proteinuria: a prospective randomized trial. International Urology and Nephrology, 2017, 49, 2195-2204.	1.4	11
295	Cardiovascular Effects of Continuous Positive Airway Pressure Treatment in Patients With Obstructive Sleep Apnea: A Meta-Analysis. Angiology, 2018, 69, 195-204.	1.8	11
296	Arterial stiffness mediates the effect of salt intake on systolic blood pressure. Journal of Clinical Hypertension, 2018, 20, 1587-1594.	2.0	11
297	Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review. Heart Failure Reviews, 2019, 24, 793-803.	3.9	11
298	Incremental haemodialysis and residual kidney function: more and more observations but no trials. Nephrology Dialysis Transplantation, 2019, 34, 1806-1811.	0.7	11
299	The Role of Uric Acid in the Acute Myocardial Infarction: A Narrative Review. Angiology, 2022, 73, 9-17.	1.8	11
300	The reproducibility of the circadian BP rhythm in treated hypertensive patients with polycystic kidney disease and mild chronic renal impairment–a prospective ABPM study. Journal of Nephrology, 2002, 15, 497-506.	2.0	11
301	Ambulatory blood pressure measurement in the renal patient. Current Hypertension Reports, 2002, 4, 369-376.	3.5	10
302	Blood pressure control in CKD stage 5D patientsare we more or less certain what to do in 2009?. Nephrology Dialysis Transplantation, 2009, 24, 3597-3601.	0.7	10
303	The EVEREST study: an international collaboration. CKJ: Clinical Kidney Journal, 2010, 3, 28-36.	2.9	10
304	Serum neutrophil gelatinase-associated lipocalin is associated with cardiovascular events in patients with chronic kidney disease. International Urology and Nephrology, 2015, 47, 1993-2001.	1.4	10
305	Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients. Angiology, 2018, 69, 449-455.	1.8	10
306	A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease: current evidence and perspectives. International Urology and Nephrology, 2019, 51, 1173-1189.	1.4	10

#	Article	IF	CITATIONS
307	<scp>Sodiumâ€glucose</scp> cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. Nephrology, 2021, 26, 1007-1017.	1.6	10
308	The success story of peritoneal dialysis in Romania: analysis of differences in mortality by dialysis modality and influence of risk factors in a national cohort. Peritoneal Dialysis International, 2006, 26, 266-75.	2.3	10
309	Acute liver failure due to leptospirosis successfully treated with MARS (molecular adsorbent) Tj ETQq1 1 0.7843	14 rgBT /(	Overlock 10 T
310	The lingering dilemma of arterial pressure in CKD: what do we know, where do we go?. Kidney International Supplements, 2011, 1, 17-20.	14.2	9
311	Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. International Urology and Nephrology, 2012, 44, 1169-1175.	1.4	9
312	A pharmacoepidemiological study of the multi-level determinants, predictors, and clinical outcomes of biosimilar epoetin alfa for renal anaemia in haemodialysis patients: background and methodology of the MONITOR-CKD5 study. Internal and Emergency Medicine, 2013, 8, 389-399.	2.0	9
313	Hormones and Arterial Stiffness in Patients with Chronic Kidney Disease. Journal of Atherosclerosis and Thrombosis, 2013, 20, 698-707.	2.0	9
314	Routine Bioimpedance-Derived Volume Assessment for All Hypertensives: A New Paradigm. American Journal of Nephrology, 2014, 40, 434-440.	3.1	9
315	New molecular insights in diabetic nephropathy. International Urology and Nephrology, 2016, 48, 373-387.	1.4	9
316	Overhydration, underhydration, and total body sodium: A tricky "ménage a trois―in dialysis patients. Seminars in Dialysis, 2018, 31, 21-25.	1.3	9
317	Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?. Current Opinion in Nephrology and Hypertension, 2018, 27, 420-425.	2.0	9
318	Eco-dialysis: fashion or necessity. International Urology and Nephrology, 2020, 52, 519-523.	1.4	9
319	Current dilemmas in inhibiting the renin–angiotensin system: do not forget real life. International Urology and Nephrology, 2007, 39, 571-576.	1.4	8
320	Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. Scientific Reports, 2015, 5, 14518.	3.3	8
321	Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials. International Urology and Nephrology, 2015, 47, 335-344.	1.4	8
322	Pro and con arguments in using alternative dialysis regimens in the frail and elderly patients. International Urology and Nephrology, 2015, 47, 1809-1816.	1.4	8
323	Iron in kidney and heart failure: from theory to practice. International Urology and Nephrology, 2018, 50, 481-493.	1.4	8
324	The role of uric acid in mineral bone disorders in chronic kidney disease. Journal of Nephrology, 2019, 32, 709-717.	2.0	8

#	Article	IF	CITATIONS
325	Immunogenicity of SARS-CoV-2 mRNA vaccine in dialysis and kidney transplant patients: A systematic review. Tuberkuloz Ve Toraks, 2021, 69, 547-560.	0.4	8
326	Analysis of Blood Pressure Variability Derived from Ambulatory Blood Pressure Monitoring in 92 Uraemic Patients. Contributions To Nephrology, 1996, 119, 157-160.	1.1	7
327	Anaemia after Renal Transplantation – Role of Immunosuppressive Drugs and a Pathophysiological Appraisal. Nephron Clinical Practice, 2006, 104, c69-c74.	2.3	7
328	Renal corpuscle morphometry with increased reliability and high level of automation. Pathology Research and Practice, 2007, 203, 9-20.	2.3	7
329	The future of European Nephrology 'Guidelines'a declaration of intent by European Renal Best Practice (ERBP). CKJ: Clinical Kidney Journal, 2009, 2, 213-221.	2.9	7
330	Modulation of the immune response to HBV vaccination by hemodialysis membranes. International Urology and Nephrology, 2010, 42, 1069-1075.	1.4	7
331	Hantavirus infection—Hemorrhagic fever with renal syndrome: the first case series reported in Romania and review of the literature. International Urology and Nephrology, 2012, 44, 1185-1191.	1.4	7
332	The impact of basal insulin analogues on glucose variability in patients with type 2 diabetes undergoing renal replacement therapy for end-stage renal disease. International Urology and Nephrology, 2016, 48, 265-270.	1.4	7
333	The impact of periodontal disease on physical and psychological domains in long-term hemodialysis patients: a cross-sectional study. International Urology and Nephrology, 2017, 49, 1261-1266.	1.4	7
334	In Reply to â€~Thoracic Ultrasound Artifacts: Still a Matter of Discussion'. American Journal of Kidney Diseases, 2018, 71, 911.	1.9	7
335	Modifications in the spectrum of bone mass predictive factors with menopausal status. Endocrine Research, 2018, 43, 176-185.	1.2	7
336	Association of intracellular lipid accumulation in subcutaneous adipocyte precursors and plasma adipokines in bariatric surgery candidates. Lipids in Health and Disease, 2019, 18, 141.	3.0	7
337	Complications of metabolic acidosis and alkalinizing therapy in chronic kidney disease patients: a clinician-directed organ-specific primer. International Urology and Nephrology, 2020, 52, 2311-2320.	1.4	7
338	Exploring Current Evidence on the Past, the Present, and the Future of the Heart Team: A Narrative Review. Cardiovascular Therapeutics, 2020, 2020, 1-8.	2.5	7
339	Sodium–glucose cotransporter inhibition in polycystic kidney disease: fact or fiction. CKJ: Clinical Kidney Journal, 2022, 15, 1275-1283.	2.9	7
340	HYPERTENSION IN HEMODIALYSIS PATIENTS: Ambulatory Blood Pressure Monitoring in Hemodialysis Patients: A Critique and Literature Review. Seminars in Dialysis, 2004, 17, 255-259.	1.3	6
341	What Do We Know and Do Not Know About Vitamin D?: A Causal Association Between Vitamin D Receptor Genetic Polymorphism and Hypertension. Journal of Clinical Hypertension, 2014, 16, 627-628.	2.0	6
342	Oral phosphate binders in CKD – is calcium the (only) answer?. Clinical Nephrology, 2014, 81, 389-395.	0.7	6

#	Article	IF	CITATIONS
343	Treatment Failure of Active Vitamin D Therapy in Chronic Kidney Disease: Predictive Factors. American Journal of Nephrology, 2015, 42, 228-236.	3.1	6
344	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
345	Severity of coronary artery disease is an independent risk factor for decline in kidney function. European Journal of Internal Medicine, 2016, 33, 93-97.	2.2	6
346	Considerations on glycaemic control in older and/or frail individuals with diabetes and advanced kidney disease. Nephrology Dialysis Transplantation, 2017, 32, 591-597.	0.7	6
347	Challenging the supremacy of evidence-based medicine through artificial intelligence: the time has come for a change of paradigms. Nephrology Dialysis Transplantation, 2020, 35, 191-194.	0.7	6
348	Strategies to Lower In-Hospital Mortality in STEMI Patients with Primary PCI: Analysing Two Years Data from a High-Volume Interventional Centre. Journal of Interventional Cardiology, 2019, 2019, 1-6.	1.2	6
349	Multiâ€modality cardiac imaging in advanced chronic kidney disease. Echocardiography, 2019, 36, 1372-1380.	0.9	6
350	Sweet dreams: therapeutic insights, targeting imaging and physiologic evidence linking sleep, melatonin and diabetic nephropathy. CKJ: Clinical Kidney Journal, 2020, 13, 522-530.	2.9	6
351	Efficiency of Hypertonic Saline in the Management of Decompensated Heart Failure: A Systematic Review and Meta-Analysis of Clinical Studies. American Journal of Cardiovascular Drugs, 2021, 21, 331-347.	2.2	6
352	Body composition, adipokines, FGF23-Klotho and bone in kidney transplantation: Is there a link?. Journal of Nephrology, 2022, 35, 293-304.	2.0	6
353	A call to optimize haemodialysis vascular access care in healthcare disrupted by COVID-19 pandemic. Journal of Nephrology, 2021, 34, 365-368.	2.0	6
354	Cardionephrology from the point of view of the cardiologist: no more agree to disagree—getting to â€~yes' for every patient. CKJ: Clinical Kidney Journal, 2021, 14, 1995-1999.	2.9	6
355	Measuring Heart Rate Variability in Patients Admitted with ST-Elevation Myocardial Infarction for the Prediction of Subsequent Cardiovascular Events: A Systematic Review. Medicina (Lithuania), 2021, 57, 1021.	2.0	6
356	Pharmacologic and interventional paradigms of diuretic resistance in congestive heart failure: a narrative review. International Urology and Nephrology, 2021, 53, 1839-1849.	1.4	6
357	The Survival of Roma Minority Patients on Chronic Hemodialysis Therapy - A Romanian Multicenter Survey. PLoS ONE, 2016, 11, e0155271.	2.5	6
358	Fatty kidney: A possible future for chronic kidney disease research. European Journal of Clinical Investigation, 2022, 52, e13748.	3.4	6
359	Pulmonary Arterial Hypertension and Adverse Outcomes after Kidney Transplantation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2022, 11, 1944.	2.4	6
360	Recent insights from studies using ambulatory blood pressure monitoring in patients with renal disease. Current Opinion in Nephrology and Hypertension, 2003, 12, 645-648.	2.0	5

#	Article	IF	CITATIONS
361	Dyspepsia in Turkish patients on continuous ambulatory peritoneal dialysis. International Urology and Nephrology, 2008, 40, 211-217.	1.4	5
362	Dialysis or not in the very elderly ESRD patient. International Urology and Nephrology, 2008, 40, 1127-1132.	1.4	5
363	Calcium and the saga of the binders: accumulating controversy, or building consensus?. International Urology and Nephrology, 2008, 40, 1009-1014.	1.4	5
364	Bone morphogenic protein-7 serum level decreases significantly in patients with contrast-induced nephropathy. International Urology and Nephrology, 2011, 43, 807-812.	1.4	5
365	Renalase: Another puzzle piece between hypertension and simple renal cysts?. International Urology and Nephrology, 2015, 47, 1181-1186.	1.4	5
366	Associations of Fibroblast Growth Factor 23 and Fetuin-A with Coronary Plaque Burden and Plaque Composition in Young Adults. Journal of Investigative Medicine, 2015, 63, 613-619.	1.6	5
367	<scp>SPRINT</scp> : The Study Nephrologists Might Take With a Grain of Salt. Journal of Clinical Hypertension, 2016, 18, 1185-1188.	2.0	5
368	FC 028COVID-19 RELATED MORTALITYÂIN KIDNEY TRANSPLANT AND DIALYSIS PATIENTS: A COMPARATIVE, PROSPECTIVE REGISTRY BASED STUDY. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	5
369	Computational Models Used to Predict Cardiovascular Complications in Chronic Kidney Disease Patients: A Systematic Review. Medicina (Lithuania), 2021, 57, 538.	2.0	5
370	Safety and Efficacy of Minimum- or Zero-Contrast IVUS–Guided Percutaneous Coronary Interventions in Chronic Kidney Disease Patients: A Systematic Review. Journal of Clinical Medicine, 2021, 10, 1996.	2.4	5
371	Evaluation of cardiovascular events and progression to end-stage renal disease in patients with dyslipidemia and chronic kidney disease from the North-Eastern area of Romania. International Urology and Nephrology, 2022, 54, 647-659.	1.4	5
372	Regression of left ventricular hypertrophy in hemodialyzed patients is possible: a follow-up study. International Urology and Nephrology, 2011, 43, 1161-1169.	1.4	4
373	Dialysis-induced segmental wall motion abnormalities, post-dialysis fatigue and cardiovascular mortality: the new Bermuda triangle?. Nephrology Dialysis Transplantation, 2013, 28, 2404-2406.	0.7	4
374	From Profusion to Confusion: The Saga of Managing Hypertension in Chronic Kidney Disease!. Journal of Clinical Hypertension, 2015, 17, 421-427.	2.0	4
375	Clinical Validation of a Peritoneal Dialysis Prescription Model in the PatientOnLine Software. Artificial Organs, 2016, 40, 144-152.	1.9	4
376	Clinical SYNTAX Score – a good predictor for renal artery stenosis in acute myocardial infarction patients: analysis from the REN-ACS trial. Archives of Medical Science, 2017, 4, 837-844.	0.9	4
377	Primary Prevention of Stroke in Chronic Kidney Disease Patients: A Scientific Update. Cerebrovascular Diseases, 2018, 45, 33-41.	1.7	4
378	Evaluation of low-dose glucocorticoid regimen in association with cyclophosphamide in patients with glomerulonephritis. International Urology and Nephrology, 2019, 51, 1805-1813.	1.4	4

#	Article	IF	CITATIONS
379	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. Journal of Nephrology, 2020, 33, 583-590.	2.0	4
380	Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. Journal of Nephrology, 2021, 34, 39-51.	2.0	4
381	A Systematic Review on Bleeding Risk Scores' Accuracy after Percutaneous Coronary Interventions in Acute and Elective Settings. Healthcare (Switzerland), 2021, 9, 148.	2.0	4
382	Involvement of KL-6 Biomarker in Interstitial Lung Disease Induced by SARS-CoV-2 Infection: A Systematic Review. Applied Sciences (Switzerland), 2021, 11, 3482.	2.5	4
383	Substitution of Sugar-Sweetened Beverages for Other Beverages: Can It Be the Next Step Towards Healthy Aging?. Current Nutrition Reports, 2021, 10, 399-412.	4.3	4
384	Left atrial strain: A novel "biomarker―for chronic kidney disease patients?. Echocardiography, 2021, 38, 2077-2082.	0.9	4
385	Proâ€Hepcidin Levels in Peritoneal Dialysis and Hemodialysis Patients. Dialysis and Transplantation, 2009, 38, 203-209.	0.2	3
386	Vitamin D Receptor Activation: Clinical Outcomes. Contributions To Nephrology, 2011, 171, 166-171.	1.1	3
387	Risk-based individualisation of target haemoglobin in haemodialysis patients with renal anaemia in the post-TREAT era: theoretical attitudes versus actual practice patterns (MONITOR-CKD5 study). International Urology and Nephrology, 2015, 47, 837-845.	1.4	3
388	Vascular Damage in Children With Chronic Kidney Disease. Hypertension, 2017, 69, 791-794.	2.7	3
389	Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?. International Urology and Nephrology, 2018, 50, 1633-1642.	1.4	3
390	<p>Invasive pulmonary infection due to <em>Thermoascus</em> <em>crustaceus</em> in a kidney transplant recipient</p> . Infection and Drug Resistance, 2019, Volume 12, 1929-1934.	2.7	3
391	Serum osmolarity as a potential predictor for contrast-induced nephropathy following elective coronary angiography. International Urology and Nephrology, 2020, 52, 541-547.	1.4	3
392	Application of survival classification and regression tree analysis for identification of subgroups of risk in patients with heart failure and reduced left ventricular ejection fraction. International Journal of Cardiovascular Imaging, 2021, 37, 1853-1861.	1.5	3
393	Molecular Genetic Approach and Evaluation of Cardiovascular Events in Patients with Clinical Familial Hypercholesterolemia Phenotype from Romania. Journal of Clinical Medicine, 2021, 10, 1399.	2.4	3
394	Assessment and Management of Volume Overload Among Patients on Chronic Dialysis. Current Vascular Pharmacology, 2020, 19, 34-40.	1.7	3
395	Halotherapy—An Ancient Natural Ally in the Management of Asthma: A Comprehensive Review. Healthcare (Switzerland), 2021, 9, 1604.	2.0	3
396	Blood pressure in dialysis patients—look before we leap. Lancet, The, 2009, 373, 1945.	13.7	2

#	Article	IF	CITATIONS
397	Medical and Surgical Management (Including Diet). Clinical Reviews in Bone and Mineral Metabolism, 2012, 10, 174-183.	0.8	2
398	Serum calcitonin and endothelial dysfunction in chronic kidney disease: a novel risk factor?. International Urology and Nephrology, 2013, 45, 151-156.	1.4	2
399	Dialysis fata morgana: can we finally successfully tackle intradialytic hypotension with plasma sodium biofeedback systems?. Nephrology Dialysis Transplantation, 2013, 28, 250-253.	0.7	2
400	Prognostic significance of 25â€hydroxivitamin <scp>D</scp> entirely explained by a higher comorbidity burden: Experience from a <scp>S</scp> outhâ€ <scp>E</scp> astern <scp>E</scp> uropean <scp>D</scp> ialysis <scp>C</scp> ohort. Hemodialysis International, 2015, 19, 249-255.	0.9	2
401	Tubular secretion in chronic kidney disease staging: a new proposal. International Urology and Nephrology, 2017, 49, 2087-2089.	1.4	2
402	Chronic kidney disease and stroke: more observations but no trials. Nephrology Dialysis Transplantation, 2018, 33, 367-370.	0.7	2
403	A Narrative Review on Thrombolytics in Advanced CKD: Is it an Evidence-Based Therapy?. Cardiovascular Drugs and Therapy, 2018, 32, 463-475.	2.6	2
404	FP003ANALYSIS OF PROGNOSTIC FACTORS FOR SURVIVAL IN A LARGE COHORT OF ETHYLENE GLYCOL INTOXICATION CASES. Nephrology Dialysis Transplantation, 2018, 33, i50-i51.	0.7	2
405	Using the SYNTAX score to predict myocardial injury early after on-pump coronary artery bypass surgery: 76 a single-centre experience analysis. Kardiochirurgia I Torakochirurgia Polska, 2020, 17, 76-82.	0.1	2
406	Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron, 2020, 144, 428-439.	1.8	2
407	â€~ <i>Will the king ever be dethroned</i> ?' The relationship and the future of oral anticoagulation therapy versus LAA closure devices. Expert Review of Cardiovascular Therapy, 2021, 19, 1-4.	1.5	2
408	Association between serum osteoprotegerin level and mortality in kidney transplant recipients ―a prospective observational cohort study. Transplant International, 2021, 34, 844-854.	1.6	2
409	Epidemiology of biopsy-proven glomerulonephritis in the past 25Âyears in the North-Eastern area of Romania. International Urology and Nephrology, 2022, 54, 365-376.	1.4	2
410	Coronary artery bypass grafting versus percutaneous coronary intervention in <scp>endâ€stage</scp> kidney disease: A systematic review and <scp>metaâ€analysis</scp> of clinical studies. Hemodialysis International, 2021, 25, 288-299.	0.9	2
411	Revisiting risk prediction tools for death and end-stage renal disease in older patients with advanced chronic kidney disease: a prospective study. International Urology and Nephrology, 2022, , 1.	1.4	2
412	The Usefulness of Assessing Heart Rate Variability in Patients with Acute Myocardial Infarction (HeaRt-V-AMI). Sensors, 2022, 22, 3571.	3.8	2
413	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Introduction: The Binders Wars 1987-2007: Double Decades of Denial, Doubt, Delay. Seminars in Dialysis, 2007, 20, 101-102.	1.3	1
414	VASCULAR CALCIFICATION IN PATIENTS WITH KIDNEY DISEASE: Final Word: The Binders Wars 2007-2017: "The Truth is Out There Somewhere…― Seminars in Dialysis, 2007, 20, 170-171.	1.3	1

#	Article	IF	CITATIONS
415	Relationships between blood pressure variability and left ventricular parameters in haemodialysis and renal transplant patients. Nephrology, 1998, 4, 87-93.	1.6	1
416	Promoting scientific collaboration and education in cardiovascular-renal medicine: EURECAM: An ERA-EDTA-based working group. CKJ: Clinical Kidney Journal, 2009, 2, 522-525.	2.9	1
417	Direct renin inhibitors: ONTARGET for success?. International Urology and Nephrology, 2009, 41, 341-355.	1.4	1
418	What to Measure at Dialysis Initiation for Reliable Prediction of Cardiovascular Outcomes: Just Look at CRP and Pulse Pressure. Peritoneal Dialysis International, 2010, 30, 280-283.	2.3	1
419	Bone morphogenic protein-7: a new prognostic marker for acute kidney injury?. CKJ: Clinical Kidney Journal, 2010, 3, 106-107.	2.9	1
420	Renal Artery Stenting in Patients With Uncontrolled Hypertension: Should We? And to Whom?. Journal of Clinical Hypertension, 2014, 16, 479-481.	2.0	1
421	Volume Overload in CKD: Pathophysiology, Assessment Techniques, Consequences and Treatment. , 2015, , 119-144.		1
422	Coronary risk score for mineral bone disease in chronic non-diabetic hemodialysis patients: results from a prospective pilot study. International Urology and Nephrology, 2017, 49, 689-700.	1.4	1
423	Can Incidental Vascular Calcifications at Mammography be Used as a Screening Biomarker for Heart and Kidney Disease?. Angiology, 2019, 70, 210-219.	1.8	1
424	Prognostic value of lung ultrasonography and bioimpedance spectroscopy in patients with heart failure and reduced ejection fraction. Archives of Medical Science, 2020, , .	0.9	1
425	Peculiarities and Consequences of Different Angiographic Patterns of STEMI Patients Receiving Coronary Angiography Only: Data from a Large Primary PCI Registry. Emergency Medicine International, 2020, 2020, 1-7.	0.8	1
426	Longer or shorter dual antiplatelet therapy in dialysis patients receiving a coronary drug-eluting stent? A rope game still ongoing. CKJ: Clinical Kidney Journal, 2020, 13, 749-752.	2.9	1
427	The Devil Is in theÂDetails When Considering the OACÂEfficacy-Safety Equation in DialysisÂPatients. Journal of the American College of Cardiology, 2020, 76, 349-350.	2.8	1
428	Clostridioides difficile Infection in Patients with Chronic Kidney Disease: A Systematic Review. BioMed Research International, 2021, 2021, 1-10.	1.9	1
429	Severe hyponatremia after direct-acting antiviral treatment in a patient with virus C compensated liver cirrhosis and kidney transplant. Journal of Gastrointestinal and Liver Diseases, 2019, 27, 203-204.	0.9	1
430	Correlation Between Recombinant Human Erythropoietin Dose and Inflammatory Status in Dialysed Patients. Revista De Chimie (discontinued), 2017, 68, 354-357.	0.4	1
431	Frailty in Older Dialysis Patients. , 2021, , 151-171.		1
432	The Association between Coffee and Caffeine Consumption and Renal Function: Insight from Individual-Level Data, Mendelian Randomization, and Meta-Analysis. Archives of Medical Science, 2021, ,	0.9	1

#	Article	IF	CITATIONS
433	Editors message. International Urology and Nephrology, 2013, 45, 1537-1537.	1.4	0
434	Epic battles in the phosphate-binder wars—the last episode?. Nature Reviews Nephrology, 2013, 9, 497-498.	9.6	0
435	Magnesium-based interventions for people with chronic kidney disease. The Cochrane Library, 2013, , .	2.8	0
436	Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 577.	1.6	0
437	FP723PULMONARY CONGESTION AND MORTALITY RISK PREDICTION IN HAEMODIALYSIS PATIENTS. Nephrology Dialysis Transplantation, 2015, 30, iii318-iii318.	0.7	0
438	FP397POST HOC ANALYSIS OF IRON INDICES IN DIALYSIS PATIENTS WITH LOWER VS HIGHER BASELINE FERRITIN IN A PHASE 3 STUDY OF SUCROFERRIC OXYHYDROXIDE. Nephrology Dialysis Transplantation, 2015, 30, iii202-iii202.	0.7	0
439	MP596WHAT IS THE BEST METHOD FOR ASSESSING FUNCTIONAL STATUS IN ELDERLY PATIENTS WITH CHRONIC KIDNEY DISEASE?. Nephrology Dialysis Transplantation, 2016, 31, i539-i540.	0.7	Ο
440	SP568WHAT IS THE BENEFIT OF DIALYSIS IN FRAIL ELDERLY PATIENTS?. Nephrology Dialysis Transplantation, 2016, 31, i282-i282.	0.7	0
441	Wnt/Sclerostin and the Relation with Vitamin D in Chronic Kidney Disease. , 2016, , 207-216.		0
442	Secondary Causes: Work-Up and Its Specificities in CKD: Influence of Volume Overload, Excess Sodium Intake and Retention in CKD. , 2017, , 169-182.		0
443	â€~ Some doors are better left closed ': Using LAA occluders as an alternative to warfarin in very high-risk dialysed patients with atrial fibrillation. International Journal of Cardiology, 2018, 262, 43-44.	1.7	0
444	Blood pressure and kidney update 2016/2017. Archives of Medical Science, 2018, , .	0.9	0
445	The influence of obstructive sleep apnea syndrome on anthropometric parameters at 12Âmonths after laparoscopic sleeve gastrectomy. Scientific Reports, 2021, 11, 5781.	3.3	0
446	Establishing links between alcohol intake, cognitive functions and type 2 diabetes. Archives of Biological Sciences, 2014, 66, 811-817.	0.5	0
447	Hemodialysis in theÂElderly. , 2019, , 147-162.		0
448	Magnesium and kidney disease. , 2022, , 345-351.		0
449	Relation Between PTH and the Risk of Mortality in CKD. , 2020, , 187-193.		0

#	Article	IF	CITATIONS
451	The role of body mass index on IgA nephropathy prognosis: a systematic review and meta-analysis. International Urology and Nephrology, 2022, , 1.	1.4	0